A drug originally developed for treating dementia may offer relief for individuals experiencing alcohol withdrawal. Researchers at the University of Kentucky have investigated an experimental medication named MW150. This drug targets brain inflammation linked to addiction and has shown promise in laboratory studies.
MW150 is designed to address mild to moderate Alzheimer’s disease. Although not yet approved, it works by impacting the p38α MAPK inflammation pathway in the brain. The research team, led by neuroinflammation expert Linda Van Eldik, conducted experiments at the Sanders-Brown Center on Aging. Their findings, published in the journal Alcohol, suggest the drug could mitigate inflammation during alcohol withdrawal.
Caleb Bailey, Ph.D., part of the research team, emphasized the drug’s potential. He explained that if additional studies confirm MW150’s effects in animal models, it could lead to new treatments for alcohol use disorder. This condition is challenging to treat, particularly due to the high relapse rates experienced during withdrawal.
Currently, MW150, along with another similar drug called Neflamapimod, is under clinical trials for dementia. Bailey noted the significance of these compounds being further developed, as they might be repurposed to treat alcohol-related conditions efficiently.
“Because they are ‘dish’-based models, they provide limited information regarding what happens in the full organism – or even the full brain,” Bailey acknowledged. Follow-up studies in living animals are needed to fully understand the impact of MW150 on systemic health and alcohol consumption.
Dr. Amy Swift, a medical officer at Silver Hill Hospital, shared her insights on the research. She stated that traditional detoxification strategies for alcohol use disorder do not address long-term drinking behavior. Supporting medications that enhance brain health could fill treatment gaps. She believes reducing neuroinflammation might help patients engage more effectively in recovery.
Bailey highlighted that no amount of alcohol consumption is beneficial for physical health. Developing pharmacological treatments to reduce the damage from chronic alcohol consumption is crucial. Minimizing alcohol intake remains the best strategy for health. As research continues, understanding the interactions between drugs like MW150 and alcohol will be vital for patient outcomes.